Tue, 18 Mar 2025 06:57:44 GMT Hang Seng Index Surges on China Growth Forecasts ... Traders now await key events, including the ISM Services PMI (forecasted at 53.5) and JOLTS Job Openings ...

TEMPE, Ariz., March 18, 2025 /PRNewswire/ -- The Institute for Supply Management® (ISM®) announces its strategic expansion from supply management to covering end-to-end supply chain management ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The CAC 40 (Cotation Assistée en Continu) is the leading index of the Paris stock exchange and is regarded as a market indicator for the general retail trends on the Euronext Paris stock exchange.

The dollar found some underlying support after the US Feb ISM services index expanded more than expected, and the Fed Beige Book said US economic activity since mid-January rose “slightly.” ...

UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism. The Calypso trial (NCT05778071) of eneboparatide ...